Fierce Pharma

Bristol Myers to build $2.3 billion manufacturing site in Houston

In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

FDA approves Replimune melanoma drug previously rejected twice

The Race to Come Up With the Next Big Sleep Drug

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

F.D.A. Approves Moderna’s mRNA Flu Vaccine

Novo Nordisk Stock Bounces Back After Surprise Earnings Report

Amgen drops ph. 1 obesity drug, upping pressure on MariTide

Lipfendra vs statins: How these cholesterol-lowering drugs compare

Pfizer Covid Pill Revenue Plunges 95%. That’s Just One Reason the Stock Is Slipping.

AstraZeneca Shares Fall on Deal Talks With Bristol-Myers

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK is implementing a $2.5 billion, three-year restructuring initiative to prioritize late-stage drug development and reorganize its research operations.

Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’

The FDA has granted approval to Otsuka for Simtriyo, marking the introduction of the first triple reuptake inhibitor for the treatment of ADHD.

Earnings live: AstraZeneca stock rises to kick off a busy earnings week

AstraZeneca shares rise after Q2 2026 earnings beat driven by strong cancer drug sales.

Trump Live Updates: FDA Peptide Meetings, Tariffs and Latest News

FDA advisory committees have issued split decisions on the legal path for peptides amid high-profile advocacy for their wider availability.

FDA panel considers easing peptide restrictions

7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Why Arrowhead Shot Sky-High, While Ionis Toppled

8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

The F.D.A. Approves a New Pill to Slash Cholesterol Levels

The FDA has approved Lipfendra, the first-of-its-kind oral PCSK9 inhibitor designed to significantly reduce cholesterol levels.

J&J Dipped On Its Report, Why Intuitive, Others Celebrated

Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits

8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector

Sanofi's Sarclisa becomes the first cancer drug approved by the FDA for delivery via an on-body injector for multiple myeloma.

AstraZeneca, Ionis report major trial failure with heart disease drug

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

FDA approves Vera Therapeutics kidney disease treatment

The FDA has approved Vera Therapeutics' drug Trutakna to treat primary IgA nephropathy, sparking a new market competition for kidney disease treatments.

Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics

7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

The FDA has launched a new initiative to accelerate the review process for new pharmaceutical manufacturing facilities.

Sanofi under antitrust probe as European Commission kicks off formal proceedings

Sanofi faces EU antitrust probe over flu vaccine marketing

European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked

European regulators are recommending the revocation of marketing authorization for Amgen's rare-disease drug Tavneos following new data.

New Drugs Are Replacing Chemo for Aggressive Breast Cancer

The FDA has granted broad first-line approval for Gilead's Trodelvy, signaling a shift away from traditional chemotherapy for aggressive breast cancer.

Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Nature retracts provocative PD-1 study that tied lung cancer survival to treatment timing